Nova Leap Health Net Income
| NVLPF Stock | USD 0.22 0.01 4.76% |
As of the 3rd of February, Nova Leap secures the Risk Adjusted Performance of 0.0351, mean deviation of 1.8, and Downside Deviation of 6.54. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nova Leap Health, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Nova Leap, which can be compared to its peers in the industry. Please verify Nova Leap Health jensen alpha, potential upside, as well as the relationship between the Potential Upside and skewness to decide if Nova Leap Health is priced some-what accurately, providing market reflects its recent price of 0.22 per share. As Nova Leap Health appears to be a penny stock we also strongly suggest to check its total risk alpha numbers.
Nova Leap's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Nova Leap's valuation are provided below:Nova Leap Health does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Nova |
Nova Leap 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Nova Leap's otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Nova Leap.
| 11/05/2025 |
| 02/03/2026 |
If you would invest 0.00 in Nova Leap on November 5, 2025 and sell it all today you would earn a total of 0.00 from holding Nova Leap Health or generate 0.0% return on investment in Nova Leap over 90 days. Nova Leap is related to or competes with Guided Therapeutics, and Vaso Corp. Nova Leap Health Corp. provides home and home health care services in the United States and Canada More
Nova Leap Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Nova Leap's otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Nova Leap Health upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 6.54 | |||
| Information Ratio | 0.0214 | |||
| Maximum Drawdown | 23.7 | |||
| Value At Risk | (4.35) | |||
| Potential Upside | 4.76 |
Nova Leap Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nova Leap's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Nova Leap's standard deviation. In reality, there are many statistical measures that can use Nova Leap historical prices to predict the future Nova Leap's volatility.| Risk Adjusted Performance | 0.0351 | |||
| Jensen Alpha | 0.1027 | |||
| Total Risk Alpha | (0.1) | |||
| Sortino Ratio | 0.0116 | |||
| Treynor Ratio | 0.2954 |
Nova Leap February 3, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0351 | |||
| Market Risk Adjusted Performance | 0.3054 | |||
| Mean Deviation | 1.8 | |||
| Semi Deviation | 2.47 | |||
| Downside Deviation | 6.54 | |||
| Coefficient Of Variation | 2694.81 | |||
| Standard Deviation | 3.55 | |||
| Variance | 12.57 | |||
| Information Ratio | 0.0214 | |||
| Jensen Alpha | 0.1027 | |||
| Total Risk Alpha | (0.1) | |||
| Sortino Ratio | 0.0116 | |||
| Treynor Ratio | 0.2954 | |||
| Maximum Drawdown | 23.7 | |||
| Value At Risk | (4.35) | |||
| Potential Upside | 4.76 | |||
| Downside Variance | 42.83 | |||
| Semi Variance | 6.1 | |||
| Expected Short fall | (6.07) | |||
| Skewness | 0.7277 | |||
| Kurtosis | 5.41 |
Nova Leap Health Backtested Returns
At this point, Nova Leap is out of control. Nova Leap Health has Sharpe Ratio of 0.0175, which conveys that the firm had a 0.0175 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Nova Leap, which you can use to evaluate the volatility of the firm. Please verify Nova Leap's Risk Adjusted Performance of 0.0351, downside deviation of 6.54, and Mean Deviation of 1.8 to check out if the risk estimate we provide is consistent with the expected return of 0.0632%. Nova Leap has a performance score of 1 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 0.41, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Nova Leap's returns are expected to increase less than the market. However, during the bear market, the loss of holding Nova Leap is expected to be smaller as well. Nova Leap Health right now secures a risk of 3.61%. Please verify Nova Leap Health potential upside and the relationship between the skewness and relative strength index , to decide if Nova Leap Health will be following its current price movements.
Auto-correlation | -0.2 |
Insignificant reverse predictability
Nova Leap Health has insignificant reverse predictability. Overlapping area represents the amount of predictability between Nova Leap time series from 5th of November 2025 to 20th of December 2025 and 20th of December 2025 to 3rd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Nova Leap Health price movement. The serial correlation of -0.2 indicates that over 20.0% of current Nova Leap price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.2 | |
| Spearman Rank Test | 0.19 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Nova Leap Health reported net income of 1.76 M. This is 99.48% lower than that of the Healthcare sector and significantly higher than that of the Medical Care Facilities industry. The net income for all United States stocks is 99.69% higher than that of the company.
Nova Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nova Leap's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Nova Leap could also be used in its relative valuation, which is a method of valuing Nova Leap by comparing valuation metrics of similar companies.Nova Leap is currently under evaluation in net income category among its peers.
Nova Fundamentals
| Return On Equity | -0.0309 | |||
| Return On Asset | -0.0294 | |||
| Profit Margin | (0.02) % | |||
| Operating Margin | (0.04) % | |||
| Current Valuation | 18.18 M | |||
| Shares Outstanding | 86.21 M | |||
| Shares Owned By Insiders | 36.06 % | |||
| Price To Earning | 10.57 X | |||
| Price To Book | 1.12 X | |||
| Price To Sales | 0.79 X | |||
| Revenue | 21.28 M | |||
| Gross Profit | 7.21 M | |||
| EBITDA | 3.74 M | |||
| Net Income | 1.76 M | |||
| Cash And Equivalents | 794.12 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 896.13 K | |||
| Debt To Equity | 0.33 % | |||
| Current Ratio | 0.87 X | |||
| Book Value Per Share | 0.22 X | |||
| Cash Flow From Operations | 2.18 M | |||
| Beta | 0.66 | |||
| Market Capitalization | 16.91 M | |||
| Total Asset | 26.77 M | |||
| Z Score | 10.8 | |||
| Net Asset | 26.77 M |
About Nova Leap Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nova Leap Health's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nova Leap using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nova Leap Health based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Nova OTC Stock
Nova Leap financial ratios help investors to determine whether Nova OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nova with respect to the benefits of owning Nova Leap security.